Our Pipeline
This page is intended for investors and commercial partners.
The Mereo BioPharma Pipeline
At Mereo, we draw on deep, trusted relationships across the pharma and biotech ecosystem to carefully select programs that have been deprioritized in other pharmaceutical and biotechnology companies for strategic reasons, but have received significant capital investment, and have the potential to transform the lives of people living with a rare disease.
Through rigorous scientific and commercial insights, flexible and capital-efficient execution, and close collaboration with patient and physician communities as well as healthcare systems, we navigate complex development challenges to create value for all our stakeholders.
The Mereo pipeline is focused on our two lead rare disease programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). In addition, we have out-licensed several other clinical stage programs.
Setrusumab (UX-143)
For the potential treatment of osteogenesis imperfecta, a rare genetic bone condition that affects children and adults.
Alvelestat (MPH966)
For the potential treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease, a rare genetic condition that results from a deficiency of alpha-1 antitrypsin.
Late-stage pipeline
1. per āshibio's website
Pipeline News and Events
Together with patient communities, healthcare professionals, partners and investors, we are constantly making progress in our mission. Keep up to date with the latest stories, developments and milestones.
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
London, UK, Solana Beach, California, and Ahmedabad, India – August 11, 2026 – Mereo BioPharma Group plc (Nasdaq: MREO), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
London, August 11, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate highlights.
